Week in Review: Zai Lab Completes $150 Million US IPO; Investors Push Valuation to $1.4 Billion

Deals and Financings   Shanghai 's Zai Lab raised $150 million in its US IPO and jumped by more than 50% upon opening, valuing the company at $1.4 billion; Shanghai Fosun Pharma acquired a scaled-down 74% stake in India 's Gland Pharma for $1.1 billion; Sisram Medical, an Israeli aesthetic laser company majority owned by (66%) by Fosun Pharma, staged a $125 million IPO in Hong Kong ; Beijing 's Bellen raised $38 million in a B funding to expand its CRO/CMO operations; Infervision, a Beijing AI/deep learning company, closed an $18 million B round to advance its automated medical scan reading products; XW Laboratories of Wuhan and Taipei raised $17.5 million in a B funding to develop a portfolio of CND drug candidates; CRO/CMO News Germany 's Merck opened a BioReliance biologics CRO/CMO in Shanghai , offering end-to-end biodevelopment services for the Asia-Pacific region;     Trials and Approvals   DelMar Pharma was approved to start a US Phase I trial of VAL-083 in ovarian cancer patients, a drug partnered with Guangxi Wuzhou Pharma;   Shuwen Biotech of Hangzhou received CE-IVD marking for its EGFR real time PCR detection kit, allowing European use of the test. Stock Symbols: (NSDQ: ZLAB) (SHA: 600196; HK: 2196) (HK: 1696) (F: MRK) (NSDQ: DMPI) Disclosure: none. Share this with colleagues: // //